Traditional ex-vivo CAR-T therapies require extracting a patient’s T cells, engineering them in specialized labs, and ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

Chimeric antigen receptor (CAR) T-cell immunotherapy was reported by ASCO in 2018 as the advance of the year. This innovative cancer treatment originated from intensive experimental work in academic ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Prof. LIANG Xingjie's team from the National Center for Nanoscience and Technology, along with Prof. GONG Ningqiang from the University of Science and Technology of China, has developed a biomimetic ...

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...

Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

A study led by Prof. Liang Xingjie's team from the National Center for Nanoscience and Technology of the Chinese Academy of ...

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...